Search
Camazepam
go.drugbank.com/drugs/DB01489ExperimentalIllicitHowever, unlike other benzodiapeines camazepam is predominantly anxiolytic and is relatively weak as an anticonvulsant, hypnotic and skeletal muscle relaxant.
Ulotaront
go.drugbank.com/drugs/DB15665Investigational[L12891] An initial clinical study has shown this drug may be effective against both positive and negative symptoms of schizophrenia.
COVID-19 convalescent plasma
go.drugbank.com/drugs/DB15692Investigationaltreatment is currently available through three main pathways: use in registered clinical trials, use through the expanded access COVID-19 protocol (21 CFR 312.305), and use for single patients through an
Covax-19™
go.drugbank.com/drugs/DB15846InvestigationalIt uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM.
Tirapazamine
go.drugbank.com/drugs/DB04858InvestigationalTirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions.
Butyrfentanyl
go.drugbank.com/drugs/DB09173ExperimentalIllicit[A182054] It is an analog of [fentanyl] with roughly 1/30 the potency.[L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic.
Pirlindole
go.drugbank.com/drugs/DB09244ExperimentalIt was developed and is currently used as an antidepressant in Russia. Its chemical structure is similar to metralindole, and it also shares pharmacological properties with this drug. … Pirlindole is a selective, reversible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A) that is approved in several European and non-European countries for the treatment of major depression.
Omburtamab
go.drugbank.com/drugs/DB15635InvestigationalCD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours. Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for us...
DDP-200
go.drugbank.com/drugs/DB05919ExperimentalDDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.